Study of the dynamics of the state of immunity, establishing criteria for its violations and timely development of their correction in patients with drug-resistant pulmonary tuberculosis during the intensive phase of treatment
Індентифікаційний номер: OffersDeveloper offers: 1. The method of correcting blood cytokine profile in patients with drug-resistant tuberculosis of the lungs; 2. A method for predicting the course of chemoresistant tuberculosis of the lungs. Method 1 - allows you to significantly increase the effectiveness of treatment of patients with drug-resistant pulmonary tuberculosis by 33.3%. Method 2 - reduces the time early, accurate and fast prediction of drug-resistant pulmonary tuberculosis flow, timely applied methods of correction of violations, which increases the effectiveness of treatment by 33.3% and speeds up the recovery of patients.
Medicine, health care
Опис пропозиції
1. To develop a method for correcting blood cytokine profile in patients with drug-resistant pulmonary tuberculosis improves the efficiency of the treatment of these patients by 33.3% (to normalize the immune system, increase the frequency of bacteriological at 96.0% and cut them for 1 month, increase the frequency of healing destruction 4.6 times). The method used TB. Effective use of technology tested in Zaporizhia oblast TB clinic clinical (duration of treatment was reduced to 1 month).
2. The developed method for predicting the course of chemoresistant tuberculosis of the lungs, primarily to improve the efficiency of treatment of patients with drug-resistant tuberculosis of the lungs. The method used TB. When TNF-α was 67.9 pg / ml, IL-6 - 50.3 pg / ml, IL-4 - 1.5 pg / ml, IL-2 - 6.7 pg / ml, IL-10 - 5 3 pg / ml, then predict disease progression.
Тип технології
Biotechnology
Процес
Сфера застосування
Medicine, phthisiology
Технічні та економічні переваги
1. Implementation of the technology allows for increasing the efficiency of treatment of patients with pulmonary tuberculosis chemoresistance by 33.3% and shorten hospital treatment in the intensive phase for 1 month.
2. Implementation of the technology allows for increasing the effectiveness of treatment of patients with drug-resistant pulmonary tuberculosis by 33.3%, to reduce the time early, accurate and fast prediction of drug-resistant pulmonary tuberculosis flow, timely applied methods of correction of violations
Практичний досвід застосування
Seller technology has many years of experience in the research field concerning the treatment of patients with chemoresistant technologies pulmonary tuberculosis
Поточна стадія: | Є результати експериментальних досліджень |
---|---|
Статус прав інтелектуальної властності: | Заявка на патент |
Умови співпраці:
Тип організації: | research organization |
---|---|
Регіони: | Країни СНД Східна Європа Центральна Європа |
Тип співпраці: | Joint further development |